LivingGLP1
Study S002041

Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT01794429
Acronym
TAO
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
45
Start
2013-02
Primary completion
2015-06
Lead sponsor
Bjorn H. Ebdrup
Conditions
Obesity; Metabolic Syndrome X; Drug-induced Obesity; Schizophrenia
Interventions
DRUG:Exenatide; DRUG:Placebo
Results posted
FALSE

Registered primary outcomes

  • Weight loss [3 months]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0010213SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity
Ishøy P, Schizophrenia bulletin
2017Randomized trialDOIcites ClinicalTrials.gov:NCT01794429
R0010620No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.
Ishøy PL, Acta psychiatrica Scandinavica
2017Randomized trialPMID 28260235DOIcites ClinicalTrials.gov:NCT01794429; registry reference DERIVED:28260235
R0010996Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.
Ishøy PL, Diabetes, obesity & metabolism
2017Randomized trialPMID 27717222DOIcites ClinicalTrials.gov:NCT01794429; registry reference DERIVED:27717222
R0020755Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
Ishøy PL, BMJ open
2014ProtocolPMID 24401727DOIcites ClinicalTrials.gov:NCT01794429; registry reference DERIVED:24401727